Morgan Stanley Surrozen, Inc. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.55 - $0.72 $143,929 - $188,416	-261,690 Reduced 33.13%	528,180 $290,000
Q1 2023 May 15, 2023	BUY	$0.56 - $1.32 $146,546 - $345,432	261,691 Added 49.55%	789,870 $473,000
Q4 2022 Feb 14, 2023	BUY	$0.42 - $41.25 $219,728 - $21.6 Million	523,162 Added 10427.79%	528,179 $306,000
Q3 2022 Nov 14, 2022	BUY	$0.26 - $46.35 $1,304 - $232,537	5,017 New	5,017 $10,000
Q2 2022 Aug 15, 2022	SELL	$2.14 - $3.43 $64 - $102	-30 Closed	0 $0
Q1 2022 Oct 27, 2022	BUY	$2.2 - $6.01 $66 - $180	30 New	30 $0
Q1 2022 May 13, 2022	SELL	$2.2 - $6.01 $114 - $312	-52 Reduced 63.41%	30 $0
Q4 2021 Feb 14, 2022	BUY	$6.0 - $9.92 $492 - $813	82 New	82 $1,000

4.52M

Ticker SRZN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,122,900
Market Cap $358M
Description
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, a...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.